- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Astellas Pharma Inc. (4503)
Astellas Pharma Inc. stock price live, this page displays TYO 4503 stock exchange data. View the 4503 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Astellas Pharma Inc. real time stock price chart below.
What Is the Astellas Pharma Inc. Stock Price Today?
The Astellas Pharma Inc. stock price today is 2,418.0.
What Is the Stock Symbol for Astellas Pharma Inc.?
The stock symbol for Astellas Pharma Inc. is "4503."
What Stock Exchange Does Astellas Pharma Inc. Trade On?
Astellas Pharma Inc. is listed and trades on the Tokyo stock exchange.
Is Astellas Pharma Inc. a Good Stock to Buy?
Determining whether Astellas Pharma Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4503 quote. (ISIN: JP3942400007)
What Is the Astellas Pharma Inc. Stock Price Today?
The Astellas Pharma Inc. stock price today is 2,418.0.
What Is the Stock Symbol for Astellas Pharma Inc.?
The stock symbol for Astellas Pharma Inc. is "4503."
What Stock Exchange Does Astellas Pharma Inc. Trade On?
Astellas Pharma Inc. is listed and trades on the Tokyo stock exchange.
Is Astellas Pharma Inc. a Good Stock to Buy?
Determining whether Astellas Pharma Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4503 quote. (ISIN: JP3942400007)
Currency in JPY
2,418.0
+81.0(+3.47%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,377.0
2,418.5
52 wk Range
1,557.5
2,717.0
4503 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,377.02,418.5
52 wk Range
1,557.52,717.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.42%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.42%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4503 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
2,476.4
Upside
+2.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 11 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
5 Buy
8 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2,476.4
(+2.42% Upside)
Astellas Pharma Inc. Earnings Call Summary for Q4/2026
- Astellas Pharma achieved record FY2025 revenue of 2,139.2B yen (+11.9% YoY), surpassing 2T yen milestone for first time in company history.
- Core operating profit surged 41.6% to 555.7B yen; net profit reached 291.6B yen despite stock declining 3.34% post-announcement to 2,468 yen.
- Strategic brands PADCEV and Xtandi drove growth with sales of 221.2B yen (+35% YoY) and 960.8B yen (+5% YoY) respectively.
- Company forecasts 50B yen decline in Xtandi sales for FY2026 due to Inflation Reduction Act impacts and upcoming patent expirations globally.
- CEO Yasukawa emphasized continued pipeline investment and operational efficiency to counter regulatory headwinds and competitive market pressures.
Last Updated: 2026-04-27, 12:22 p/m
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
79.15 / 51.83
Revenue / Forecast
640.91B / 565.97B
Compare 4503 to Peers and Sector
Metrics to compare | 4503 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4503PeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.5x | 19.2x | −0.3x | |
PEG Ratio | 0.03 | 0.20 | 0.00 | |
Price/Book | 2.2x | 2.4x | 2.6x | |
Price / LTM Sales | 1.8x | 2.4x | 3.1x | |
Upside (Analyst Target) | 7.0% | 15.4% | 48.5% | |
Fair Value Upside | Unlock | 10.7% | 6.3% | Unlock |
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Astellas Pharma Inc. (4503) Stock Price Today?
The Astellas Pharma Inc. stock price today is 2,418.0 JPY.
What Stock Exchange Does Astellas Pharma Inc. Trade On?
Astellas Pharma Inc. is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for Astellas Pharma Inc.?
The stock symbol for Astellas Pharma Inc. is "4503."
Does Astellas Pharma Inc. Pay Dividends? What’s The Current Dividend Yield?
The Astellas Pharma Inc. dividend yield is 3.42%.
What Is the Astellas Pharma Inc. Market Cap?
As of today, Astellas Pharma Inc. market cap is 4.19T JPY.
What Is Astellas Pharma Inc.'s Earnings Per Share (TTM)?
The Astellas Pharma Inc. EPS (TTM) is 203.0.
When Is the Next Astellas Pharma Inc. Earnings Date?
Astellas Pharma Inc. will release its next earnings report on Nov 04, 2026.
From a Technical Analysis Perspective, Is 4503 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Astellas Pharma Inc. Stock Split?
Astellas Pharma Inc. has split 1 times.
How Many Employees Does Astellas Pharma Inc. Have?
Astellas Pharma Inc. has 14099 employees.
What is the current trading status of Astellas Pharma Inc. (4503)?
As of Aug 20, 2026, Astellas Pharma Inc. (4503) is trading at a price of 2,418.0 JPY, with a previous close of 2,337.0 JPY. The stock has fluctuated within a day range of 2,377.0 JPY to 2,418.5 JPY, while its 52-week range spans from 1,557.5 JPY to 2,717.0 JPY.
What Is Astellas Pharma Inc. (4503) Price Target According to Analysts?
The average 12-month price target for Astellas Pharma Inc. is 2,476.4 JPY, with a high estimate of 3100 JPY and a low estimate of 1700 JPY. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +2.42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.